{"preliminary_commentary":{"by_channel":{"podcast":6,"youtube":1,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT03805841\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["tarloxotinib"]],"indication":null,"name":"RAIN","nct_id":"NCT03805841","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=rain-nct03805841. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"RAIN","arms":[{"description":"tarloxotinib bromide","label":"Active","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2021-04-23","type":"ACTUAL"},"conditions":["NSCLC, Stage IV","NSCLC Stage IIIB","NSCLC, Stage IIIC","NSCLC, Recurrent","EGFR Exon 20 Insertion Mutation","HER2-activating Mutation","ERBB Fusion","NRG1 Fusion"],"enrollment":{"count":41,"type":"ACTUAL"},"has_results":true,"interventions":[{"name":"tarloxotinib bromide","otherNames":["Tarlox","tarloxotinib"],"type":"DRUG"}],"last_update":"2023-06-28","lead_sponsor":"Rain Oncology Inc","official_title":"Phase 2 Study - Evaluate the Clinical Activity of Tarloxotinib in Patients With Non-Small Cell Lung Cancer That Harbors an EGFR Exon 20 Insertion or HER2-Activating Mutation and Other Advanced Solid Tumors With NRG1/ERBB Family Gene Fusions","overall_status":"TERMINATED","phases":["PHASE2"],"primary_completion_date":{"date":"2021-04-09","type":"ACTUAL"},"primary_outcomes":[{"measure":"ORR","timeFrame":"Through study completion, an average of 10 months."}],"references":[{"citation":"Ye L, Chen X, Zhou F. EGFR-mutant NSCLC: emerging novel drugs. Curr Opin Oncol. 2021 Jan;33(1):87-94. doi: 10.1097/CCO.0000000000000701.","pmid":"33122578","type":"DERIVED"}],"start_date":{"date":"2019-03-13","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumors With NRG1/ERBB Gene Fusions","url":"https://clinicaltrials.gov/study/NCT03805841"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/rain-nct03805841"}